Company news
Azitra Inc news in 2025
Azitra Inc's news releases, calls and decks from 2025, newest first.
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
December 17, 2025
Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules
November 24, 2025
Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates
November 12, 2025
Azitra, Inc. Addresses False Report Regarding Sale of Securities
November 7, 2025
Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris
October 20, 2025
Azitra to Participate in Dermatologic Rare Disease Panel at Maxim Growth Summit
October 15, 2025
Azitra Receives Notice of Non-Compliance from NYSE American
October 3, 2025
Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 4, 2025
Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash
August 27, 2025
Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates
August 11, 2025
Azitra, Inc. Announces Reverse Stock Split
August 11, 2025
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
June 17, 2025
Azitra, Inc. Announces Presentation at the 2025 BIO International Convention
June 10, 2025
Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash
May 28, 2025
Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash
May 14, 2025
Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates
May 13, 2025
Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025
April 25, 2025
Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline
April 24, 2025